{"entity":{"id":"sarcomatoid-rcc","kind":"term","name":"Sarcomatoid differentiation (RCC)","aka":[],"tldr":"A spindle-cell change found in about 10% of kidney cancers that makes them aggressive and, unexpectedly, unusually responsive to immunotherapy.","summary":"Sarcomatoid RCC (any histology) has median survival under a year on TKIs alone, but in CheckMate 214 nivolumab-ipilimumab produced ORR ~60% and complete responses in ~20%, with OS HR ~0.45. High PD-L1 and immune infiltration explain the paradox. Guidelines favour IO-based regimens in sarcomatoid disease.","asOf":"2026-09-07","wikipedia":"https://en.wikipedia.org/wiki/Sarcomatoid_carcinoma","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Sarcomatoid_carcinoma"}],"tags":[],"related":[],"cancers":["rcc"],"sections":[],"technologies":[],"targets":[],"drugs":["nivolumab","ipilimumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["checkmate-214"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"category":"Pathology"},"route":"/terms/sarcomatoid-rcc/","neighbours":{"cancer":[{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"}],"drug":[{"id":"ipilimumab","kind":"drug","name":"Ipilimumab","route":"/drugs/ipilimumab/"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"}],"trial":[{"id":"checkmate-214","kind":"trial","name":"CheckMate 214","route":"/trials/checkmate-214/"}],"pairing":[{"id":"risk-directed-first-line-rcc","kind":"pairing","name":"IMDC risk → first-line regimen choice (RCC)","route":"/pairings/risk-directed-first-line-rcc/"}]}}